Black Product Managers Hosts Inaugural Summit Building the Best Career Roadmap for Success

Product leaders from Facebook, YouTube, Google, and VICE Media speak at career event for nationwide community of Black professionals in product

SAN FRANCISCO, March 26, 2021 (GLOBE NEWSWIRE) — On February 24, 2021, Black Product Managers, the first organization to build a nationwide network for Black professionals in product, hosted its inaugural summit “Building the Best Career Roadmap for Success.” Over the course of two days, BPM welcomed industry leaders in product to its virtual summit to share career insights on entering and growing in the field of product, exclusively for members of BPM’s network.

“It was incredibly validating to have key leaders in our industry speak at our first conference. It punctuated the work BPM has been doing these last few years to create tangible career opportunities for Black talent in tech,” said Brittany Bankston, President and Co-Founder of Black Product Managers. “We hope conferences like these can highlight how crucial it is to invest in Black talent in tech, and product specifically – it impacts a company’s growth, its base of users, and the quality of its product.”

Speakers for this year’s conference included Jackie Bavaro, Co-Author of “Cracking the PM Interview” and Former Head of Product at Asana; Oji Udezue, CPO of Parsable and Former CPO of Calendly; Adam Thomas, Principal at Approaching One; Angel Onuoha, Associate Product Manager at Google; Todd Sherman, Group Product Leader at YouTube; and Breana Jones, Director of Product at Vice. Key learnings from the conference were circulated internally within the BPM organization for attendees unable to tune into the live broadcast.

“The entrance into Product is elusive and often hard to navigate if you don’t have a network already involved in the sector – which is why events like these, and the work BPM is doing more broadly to create inroads for Black talent, are so critical,” said Jackie Bavaro, former Head of Product Management at Asana and author of Cracking the PM Interview.

Black Product Managers regularly hosts internal workshops, networking events, and an Accelerator program geared at equipping members with tools to earn promotions, raises, and other career milestones. The organization, founded in 2017, was originally created to serve as a community and resource group for Black product managers across industries, and ultimately find ways to propel Black technical talent into leadership roles. The organization has members from across the United States, the United Kingdom, and Nigeria – and aims to be the largest community of Black PMs in the world.

To learn more about Black Product Managers, how to get involved, and upcoming news, visit https://www.blackproductmanagers.com.

About Black Product Managers

Black Product Managers was founded in 2017 to create the first nationwide network for Black professionals working in product. Today it’s grown into a community of over 800 Black technologists from some of tech’s most prominent companies – with the goal of reaching every Black PM across the globe. On a mission to help Black product managers advance their careers and become product leaders, BPM is reshaping the tech industry to create more representation and leverage across product management at scale.

Media Contact


[email protected]



Proactive news headlines including Lucky Minerals, Tetra Bio-Pharma, First Cobalt and CleanSpark

Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:

New York, March 26, 2021 (GLOBE NEWSWIRE) —

  • Naturally Splendid (CVE:NSP) (OTCMKTS:NSPDF) (FRA:50N)  appoints digital marketing veteran Kris Tarr as VP of e-commerce click here
  • Lucky Minerals Inc (TSXV:LKY) (OTCPINK:LKMNF) (FRA:LKY) taps venture capital veteran Diane Mann to serve as corporate secretary click here
  • First Cobalt Corp (CVE:FCC) (OTCQX:FTSSF) (FRA:18P) strikes amended loan deal with giant Glencore; to pay off debt with shares click here
  • Tetra Bio-Pharma Inc (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1)  initiates additional studies on lead drug candidate ARDS-003 click here
  • Vuzix Corporation (NASDAQ:VUZI) prices underwritten public offering at $20.50 per share, with gross proceeds expected to be approximately $85M click here
  • CleanSpark Inc (NASDAQ:CLSK) buys 4,778 more Bitcoin mining rigs, works toward carbon-free mining click here

About Proactive

With six offices on three continents and a team of experienced business journalists and broadcasters, Proactive works with innovative growth companies quoted on the world’s major stock exchanges, helping executives engage intelligently with investors.

Proactive’ s platform delivers the right message to the right audience, digitally and in real time, leveraging a range of media, investment research, digital investor targeting and website development services to support over 1,000 fast-growing companies globally.

Proactive’s network reaches over 12 million engaged private, professional and institutional investors looking for opportunities.

•           Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month.

•           We syndicate our content to hundreds of mainstream and specialist news sites that expand our reach into networks that can be difficult for press releases to penetrate.

•           We custom build corporate websites from the ground up, empowering clients and their brands with a modern online presence and the latest insight on effective SEO strategy.

•           Our news coverage ranks high on the world’s most popular search platforms, and we can further amplify online presence and outreach with sophisticated digital investor targeting.

•           We help the world understand what makes companies stand out from the crowd with in-depth investment research from a team of experienced analysts.

For more information on how Proactive can help you make a difference, email us at [email protected]



SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ontrak, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

PR Newswire

LOS ANGELES, March 26, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ontrak, Inc. (“Ontrak” or “the Company”) (NASDAQ: OTRK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between November 5, 2020 and February 26, 2021, inclusive (the ”Class Period”), are encouraged to contact the firm before May 3, 2021.    

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Ontrak’s largest customer gauged the Company’s performance on the basis of reaching the lowest cost per medical visit possible rather than patient outcomes or medical cost savings. This customer found the Company’s program to be ineffective and was likely to terminate its contract. Because this customer represented a significant portion of the Company’s revenue, the loss of this contract would have a significant impact on its financial results. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Ontrak, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com 
Office: 310-301-3335
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-action-notice-the-schall-law-firm-reminds-investors-of-a-class-action-lawsuit-against-ontrak-inc-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-301256895.html

SOURCE The Schall Law Firm

Genscript Biotech Reports Full Year 2020 Financial Results

– Achieved Historical High Revenue- Non-Cell Therapy Segment Shows Over 100%+ Adjusted Net Profit Growth

PR Newswire

Highlights:

  • Revenue of the Group for the year ended December 31, 2020 was approximately US$390.8 million, representing an increase of 42.9% as compared with approximately US$273.4 million for the year ended December 31, 2019
  • Gross profit of the Group for the year ended December 31, 2020 was approximately US$255.9 million, representing an increase of 41.9% as compared with approximately US$180.3 million recorded for the year ended December 31, 2019
  • The adjusted net profit* of non-cell therapy business was approximately US$44.4 million, representing an increase of 105.6% as compared with approximately US$21.6 million for the year ended December 31, 2019, and the adjusted net loss* of cell therapy business was approximately US$213.3 million, whilst the adjusted net loss* of cell therapy business was approximately US$131.9 million for the year ended December 31, 2019
  • Loss of the Group for the year ended December 31, 2020 was approximately US$281.4 million, whilst loss was approximately US$117.5 million for the year ended December 31, 2019. The adjusted net loss* of the Group was approximately US$168.9 million, whilst the adjusted net loss* of approximately US$110.3 million was recorded for the year ended December 31, 2019

NANJING, China, March 26, 2021 /PRNewswire/ — Genscript Biotech (HKEX: 1548.HK) (GenScript), a global leading biotech company, today announced its audited financial results for the year ended December 31, 2020.

“In 2020, the outbreak of COVID-19 pandemic presented both challenges and opportunities to the life science community. Thanks to concerted efforts of all GenScript people, the Group delivered historically strong results amid the outbreak,” said Patrick Liu, Rotating CEO of GenScript. “In the past year, our business segments tided over difficulties, turned challenges into opportunities and achieved many breakthroughs. In the future, we will move forward with dedication and create more value for both our investors and customers. We are committed to our mission of “making people and nature healthier through biotechnology” and strive for human wellbeing.”

Financial Results Highlits for the Year Ended December 31, 2020

Revenue                                            

In 2020, the Group recorded revenue of  approximately US$390.8 million, representing an  increase of 42.9% from approximately US$273.4 million in 2019. This was primarily attributable to (i) the strong growth in business of specially-functioned protein and antibody which meet market demands on key products related to COVID-19, (ii) the continuing increase from life-science services and products from major strategic customers and new competitive services and products, (iii) the  increase of contract revenue derived from Legend’s collaboration with Janssen with new milestone achieved, and (iv) the increase in both the number of customers and their purchase volume of industrial synthetic biology products.

Gross Profit

In 2020, the Group’s gross profit increased by 41.9% to approximately US$255.9 million from approximately US$180.3 million in 2019. The increase in gross profit was primarily attributable       to the (i) strong growth in life-science and biologics development business and high gross margin products, especially for COVID-19, and (ii) significant improvement on capacity utilization of materials and labor efficiency in industrial synthetic biology products.

Selling and distribution expenses

The selling and distribution expenses increased by 52.4% to approximately US$107.3 million in    2020 from approximately US$70.4 million in 2019. This was mainly attributable to the (i) increased investment into the commercial talent pool by recruiting more experienced personnel and improving incentive packages, and (ii) increased expenses for the global expansion of our business.

Administrative expenses

In 2020, the administrative expenses increased by 63.3% to approximately US$90.3 million from US$55.3 million in  2019. This was  mainly caused by  (i)  competitive compensation package for  our employees including shared-based payment provided to recruit experienced talents for all business segments, (ii) the reinforcement of some key administrative functions such as information technology, supply chain and finance to build up capable and professional administrative team to support the Group’s overall business expansion, and (iii) the expansion of the European and Asia- Pacific Regional centers to accelerate the Group’s global market penetration.

Research and development expenses

The  research and  development expenses increased by  41.6% to  approximately US$263.4 million  in 2020 from approximately US$186.0 million in 2019. This was mainly due to the (i)  investment    in COVID-19 related projects and other new challenging  research  and  development  projects,  which significantly strengthened our competitiveness in the market and improved our production efficiency, (ii) increase in clinical trial expenses and preclinical study costs, especially in the cell therapy segment, and (iii) increase in compensation package including shared-based payment for research and development personnel.

*Adjusted net profit/(loss)


Non-cell



therapy




US$’000


Cell therapy




US$’000


Total




US$’000

Net profit/(loss)


22,054


(303,477)


(281,423)

Excluding: Share-based payment expenses, net of tax


10,904


4,760


15,664

Exchange differences, net of tax


6,526


(66)


6,460

Consultation expenses for the Investigation, net of tax


1,086




1,086

Impairment loss on goodwill, other intangible assets and

long-term investments, net of tax


3,806




3,806

Fair value loss of convertible redeemable preferred shares




79,984


79,984

Service fee for the issuance of Legend Series A Preference Shares




4,014


4,014

Spin-off expenses relating to the separate listing of Legend


24


1,439


1,463

Adjusted net profit/(loss)


44,400

 



(213,346)


(168,946)

 


CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME


REVENUE


2020




US$’000




390,846

2019


US$’000


273,354

Cost of sales


(134,953)

(93,064)

Gross profit


255,893

180,290

Other income and gains


24,795

21,185

Selling and distribution expenses


(107,341)

(70,358)

Administrative expenses


(90,341)

(55,256)

Research and development expenses


(263,401)

(186,022)

Fair value loss of convertible redeemable preferred shares


(79,984)

Finance costs


(5,432)

(781)

Other expenses


(15,497)

(589)

Share of losses of associates


(599)

(308)

Reversal of/(provision for) impairment of financial
assets, net


7

(1,851)


LOSS BEFORE TAX


(281,900)

(113,690)

Income tax credit/(expense)


477

(3,826)


LOSS FOR THE YEAR


(281,423)

(117,516)

Attributable to: Owners of the parent


(204,945)

(96,912)

Non-controlling interests


(76,478)

(20,604)

 


(281,423)

 

(117,516)

 


CONSOLIDATED STATEMENT OF FINANCIAL POSITION

 


NON-CURRENT ASSETS


2020



US$’000

2019


US$’000

Property, plant and equipment


345,215

235,986

Advance payments for property, plant and equipment


5,906

8,585

Investment properties


7,726

7,442

Right-of-use asset


34,017

29,642

Goodwill


14,116

15,245

Other intangible assets


26,020

25,482

Investment in associates


3,433

2,615

Financial assets at fair value through profit or loss


10,555

4,667

Other non-current asset


3,542

Deferred tax assets


3,702

5,701

Total non-current assets


454,232

335,365


CURRENT ASSETS


Inventories

 


31,745

 

16,486

Contract costs


5,785

3,369

Trade and notes receivables


141,748

73,067

Prepayments, other receivables and other assets


32,834

31,621

Financial assets at fair value through profit or loss


5,866

25,434

Loans to an associate


2,422

2,007

Restricted cash


7,471

972

Time deposits


136,245

148,693

Cash and cash equivalents


629,058

252,397

Total current assets


993,174

554,046

 


CONSOLIDATED STATEMENT OF FINANCIAL POSITION

 


CURRENT LIABILITIES


2020




US$’000



2019


US$’000


Trade and bills payables


23,376

17,627

Other payables and accruals


168,980

125,035

Interest-bearing bank borrowings


44,642

17,008

Lease liabilities


2,588

1,769

Tax payable


3,532

2,846

Contract liabilities


84,414

60,130

Government grants


379

90

Total current liabilities


327,911

224,505


NET CURRENT ASSETS


665,263

329,541


TOTAL ASSETS LESS CURRENT LIABILITIES


1,119,495

664,906


NON-CURRENT LIABILITIES


Interest-bearing bank loans

 


1,260

1,748

Lease liabilities


6,513

3,608

Contract liabilities


277,052

277,827

Deferred tax liabilities


7,030

5,582

Government grants


11,495

3,843

Other non-current liability


554

Total non-current liabilities

 



303,904

292,608


NET ASSETS

 


815,591

372,298


EQUITY

Equity attributable to owners of the parent

Share capital

 


1,954

 

1,879

Treasury shares


(16,712)

(7,774)

Reserves


916,463

388,699

 


901,705

382,804

Non-controlling interests


(86,114)

(10,506)


TOTAL EQUITY

 



815,591

372,298

 

About GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform and the industrial synthesis product platform. GenScript’s business operation spans over 100 countries and regions worldwide with legal entities located in the US, the Chinese mainland, Hong Kong of China, Japan, Singapore, Netherlands and Ireland.

 

Cision View original content:http://www.prnewswire.com/news-releases/genscript-biotech-reports-full-year-2020-financial-results-301256894.html

SOURCE GenScript Biotech Corporation

Agromart & Sollio Face Class Action for Privacy Breach

Lawsuit suggests negligent collection, storage and security of sensitive information

LONDON, Ontario, March 26, 2021 (GLOBE NEWSWIRE) — A proposed class action lawsuit has been filed in the Ontario Superior Court of Justice against Sollio Agriculture L.P. (“Sollio”) and Agronomy Company of Canada (“Agromart”) following a cyber-attack on or about May 27, 2020 (the “Breach”). The claim is brought on behalf of residents of Canada whose personal information was collected and stored on the defendants’ computer systems, and that was compromised or accessed in the Breach.

Following the breach, the bank accounts of the plaintiff were compromised.

The claim alleges that hackers were able to penetrate Agromart and Sollio’s computer systems because their cyber security systems were substandard. The hackers then extracted the confidential and sensitive personal information of thousands of Canadian farmers, and made it accessible to malevolent actors on the deep or dark web. The claim alleges that the amount of personal information that the defendants acquired from their customers, and then carelessly stored, exceeds the amount of information that was reasonably necessary for their operations.

The claim alleges that Sollio and Agromart were negligent, invaded the proposed class members’ privacy, and breached various statutory duties, all of which lead to the Breach.

As a result of the Breach, the claim alleges that the class members’ personal information has been compromised and that they have suffered damages. This class action seeks to obtain compensation for the losses the proposed class members have suffered from the Breach.

The proposed class is represented by Foreman & Company Professional Corporation and Waddell Phillips Professional Corporation. Although there is no action required at this time from proposed class members, anyone seeking more information, or who wishes to receive direct updates or any court-approved notices can request to be added to a list of potential claimants by emailing [email protected].

Contacts:

Jonathan Foreman, Foreman & Company Professional Corporation
519-914-1175
[email protected]

Margaret Waddell, Waddell Phillips Professional Corporation
1-800-430-3107
[email protected]



WildBrain Completes Refinancing of Credit Facilities

PR Newswire

Term Loan Maturity Extended to March 2028

HALIFAX, NS, March 26, 2021 /PRNewswire/ – WildBrain Ltd. (“WildBrain” or the “Company“) (TSX: WILD), a global leader in kids and family entertainment, has completed the refinancing of its senior secured term loan with a new seven-year, US$285 million senior secured term loan facility (the “Term Loan“), maturing in March 2028. The Term Loan has no financial maintenance covenant and bears interest at a rate of LIBOR plus 4.25%.

The Company has also entered into a new five-year, US$30 million revolving credit facility (the “Revolving Facility“) with an interest rate of LIBOR plus 4.00%. The Revolving Facility does not carry a financial maintenance covenant, except when amounts are drawn and outstanding. The Revolving Facility matures on the earlier of March 2026 or three months prior to the maturity of the Company’s convertible debentures, except where converted.

The net proceeds of the Term Loan were used to repay the existing US$276.5 million term facility maturing in December 2023. The Revolving Facility replaces the existing undrawn US$30 million revolving credit facility maturing in June 2022.

Eric Ellenbogen, CEO of WildBrain, said: “We have been hard at work over the past 20 months repositioning our assets for meaningful, long-term growth. With two major IP deals announced in the past six months and a robust deal pipeline, we are now well on our way to executing our strategic vision. Credit markets have taken notice of our improving financial performance and earnings trajectory, enabling us to refinance our term loan and our revolver at attractive terms. We added significant duration to both of these instruments while also removing the financial maintenance covenant on the term loan. This enhanced capital structure affords us significant strategic and financial flexibility to further drive our digital, content and brand strategies.”

RBC Capital Markets acted as sole lead arranger and bookrunner on the refinancing. The credit agreement in respect of the Term Loan and Revolving Facility will be available on SEDAR at www.sedar.com.

For more information, please contact:

Investor Relations: Nancy Chan-Palmateer – Director, Investor Relations, WildBrain
[email protected]
+1 416-977-7358

Media: Shaun Smith – Director, Corporate & Trade Communications, WildBrain
[email protected]
+1 416-977-7230

About WildBrain

At WildBrain we inspire imaginations to run wild, engaging kids and families everywhere with great content across all media. With approximately 13,000 half-hours of filmed entertainment in our library – one of the world’s most extensive – we are home to such brands as Peanuts, Teletubbies, Strawberry Shortcake, Caillou, Inspector Gadget, Johnny Test and Degrassi. At our 75,000-square-foot state-of-the-art animation studio in Vancouver, BC, we produce such fan-favourite series as The Snoopy Show, Snoopy in Space, Chip & Potato, Carmen Sandiego, Go, Dog. Go! and more. Our shows are enjoyed worldwide in more than 150 countries on over 500 streaming platforms and telecasters, and our AVOD business – WildBrain Spark – offers one of the largest networks of kids’ channels on YouTube, garnering billions of views per month from over 150 million subscribers. We also license consumer products and location-based entertainment in every major territory for our own properties as well as for our clients and content partners. Our television group owns and operates four family entertainment channels that are among the most viewed in Canada. WildBrain is headquartered in Canada with offices worldwide and trades on the Toronto Stock Exchange (TSX: WILD). Please visit us at wildbrain.com.

Forward-Looking Statements

This press release contains “forward-looking statements” under applicable securities laws with respect to the Company including, without limitation, statements regarding a refinancing by the Company and associated credit facilities, the Company’s deal pipeline, the Company’s financial flexibility, the future financial and operating performance of the Company, and the business strategies and operational activities of the Company. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties and are based on information currently available to the Company. Actual results or events may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations, among other things, include epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, the magnitude and length of economic disruption as a result of the worldwide COVID-19 outbreak, the ability of the Company to complete deals and execute on its business strategies, market factors, and risk factors discussed in materials filed with applicable securities regulatory authorities from time to time including matters discussed under “Risk Factors” in the Company’s most recent Annual Information Form and annual Management Discussion and Analysis. These forward-looking statements are made as of the date hereof, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/wildbrain-completes-refinancing-of-credit-facilities-301256878.html

SOURCE WildBrain Ltd.

Medtronic Receives FDA Approval for “Breakthrough” Transcatheter Pulmonary Valve Replacement for Patients with Congenital Heart Disease

Harmony™ Transcatheter Pulmonary Valve is First Minimally Invasive Alternative for Patients with Severe Pulmonary Regurgitation Who Have a Native or Surgically-Repaired Right Ventricular Outflow Tract

PR Newswire

DUBLIN, March 26, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for its Harmony™ Transcatheter Pulmonary Valve (TPV), the first minimally invasive therapy created to treat patients with a specific type of congenital heart defect of the right ventricle (RV), one of the four chambers of the heart, which makes it difficult for blood to travel from the heart to the lungs. The Harmony TPV, which is placed inside a patient’s native anatomy during a catheter-based procedure, was designated as a Breakthrough Therapy under FDA’s Breakthrough Device Designation (BDD) program, an approval pathway intended to help patients receive more timely access to certain life-saving technologies.

Congenital heart disease (CHD) is the most common type of birth defect in the United States, affecting an estimated 40,000 infants each year1 and about 1.6 million adults currently living with congenital heart disease2.

“The typical congenital heart disease patient will face a multitude of open-heart surgeries over their lifetime, to continually address issues with their pulmonary valve. Furthermore, congenital heart disease patients require lifelong monitoring, preventive care and specialized treatment all the way from childhood to adulthood,” said Matthew J. Gillespie, M.D., attending interventional cardiologist, co-director of the Pediatric Valve Center and director of the Cardiac Catheterization Laboratory at Children’s Hospital of Philadelphia, and principal investigator in the Harmony TPV Clinical Study.

Approximately one in five patients born with CHD have structural malformations that disrupt the connection between the heart and the lungs3, called the right ventricular outflow tract (RVOT). The standard of care today in the U.S. requires that these patients receive open-heart surgery or other interventions early in life to address these malformations. Some of these patients may become candidates for the Medtronic Melody® TPV later in life, the first transcatheter heart valve shown to effectively delay open-heart surgery. For the 80% of CHD patients who require a native or surgically repaired RVOT at birth, many will need a pulmonary valve replacement later in life, which historically has required another open-heart surgery. The Harmony TPV provides these patients with an alternative to the more invasive open-heart surgical approach; instead, the valve is loaded onto a catheter and delivered via a small incision in the femoral vein or in the neck and placed directly inside the heart.

“The availability of the Harmony TPV will allow a broader range of congenital heart disease patients access to transcatheter technology,” said Nina Goodheart, president of the Structural Heart & Aortic business, which is part of the Cardiovascular Portfolio at Medtronic. “Harmony TPV’s novel attributes make it the only non-surgical solution designed to adapt to a wide variety of anatomies for this specific patient population living with congenital heart disease.”

The FDA approval is based on clinical data from the Harmony TPV clinical study that showed excellent safety (freedom from mortality) and effectiveness (acceptable hemodynamic function) at 30 days and six months, respectively. Data from the study also showed patients treated with Harmony TPV experienced no significant reinterventions, reoperations or endocarditis at six months.

The Harmony TPV qualified as a proof of concept product for the Harmonization by Doing (HBD) for Children program. The HBD for Children program was established as a partnership among stakeholders of academia, industry and regulatory agencies in Japan and the United States, with a primary focus on the development of pediatric devices as the development of medical devices for pediatric use lags behind that of medical devices for adults in both countries. The Harmony TPV device is available for use in the United States. Outside of the U.S., Harmony TPV is limited to investigational use and not approved for sale or distribution.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.


About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 Hoffman JL, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890-1900.
2 Adult Congenital Heart Association (ACHA).
3 McElhinney DB, Hennesen JT. The Melody® valve and Ensemble® delivery system for transcatheter pulmonary valve replacement. Ann NY Acad Sci. 2013; 1291: 77-85.

 


Contacts:

Joey Lomicky

Ryan Weispfenning

Public Relations

Investor Relations

+1-612-239-1823 

+1-763-505-4626

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/medtronic-receives-fda-approval-for-breakthrough-transcatheter-pulmonary-valve-replacement-for-patients-with-congenital-heart-disease-301256890.html

SOURCE Medtronic plc

INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Plug Power Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

PR Newswire

LOS ANGELES, March 26, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Plug Power Inc. (“Plug Power” or “the Company”) (NASDAQ: PLUG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between November 9, 2020 and March 1, 2021, inclusive (the ”Class Period”), are encouraged to contact the firm before May 7, 2021.    

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Plug Power failed to file its annual report for 2020 in a timely manner due to delays in reviewing the classification of certain costs and other matters. The Company was likely to report a failure to maintain appropriate internal controls over financial reporting. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Plug Power, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/investor-action-reminder-the-schall-law-firm-reminds-investors-of-a-class-action-lawsuit-against-plug-power-inc-and-encourages-investors-with-losses-in-excess-of-250-000-to-contact-the-firm-301256886.html

SOURCE The Schall Law Firm

NetDragon Announces Fiscal Year 2020 Financial Results

Operating Profit Rose 40% to Record High of RMB 1.1 Billion

PR Newswire

HONG KONG, March 25, 2021 /PRNewswire/ — NetDragon Websoft Holdings Limited (“NetDragon” or the “Company”; Hong Kong Stock Code: 777), a global leader in building internet communities, today announced its financial results for fiscal year 2020. NetDragon’s management team will hold a conference call and webcast at 10:00amHong Kong time on 26 March 2021 to discuss the results and recent business developments.

Mr. Dejian Liu, Chairman of NetDragon, commented: “The year of 2020 marked the 10th consecutive year of revenue growth for NetDragon as we continue to focus on growing our business and strengthening our core competencies during the Covid-19 pandemic.”

“The pandemic has brought on both unprecedented opportunities and challenges. We have seen accelerating adoption of technology in the education space, a trend which is widely believed to continue in the post-Covid-19 world. Thanks to our years of research and development effort, our one-stop blended learning solutions have enabled us to capitalize on a new market opportunity to address the holistic edtech needs of countries around the world. We believe 2020 is a year of validation of our country model, as we succeeded in commencing our first country-wide rollout in Egypt, as well as expanding our model into a growing list of countries such as Ghana, Thailand and Malaysia. Our flagship classroom technology subsidiary Promethean also saw strong momentum in the second half of 2020 and continued to maintain its global market leadership position, being number one in market share in eight of our top ten countries by revenue contribution[1].”

“In China, we continued to focus on broadening user coverage and driving user engagement across multiple product categories in order to prepare ourselves to scale future monetization. With monthly teachers’ active installed base of over 1.5 million in December 2020, 101 Education PPT has become one of the most popular lesson preparation and delivery platforms in China, providing us with a solid foundation to roll out paid value-added services, such as live broadcast service which we started to pilot in the second half of 2020. Meanwhile, One-Stop Learning platform expanded our “to G” penetration to nine provinces during the year, including the provinces of Hubei, Henan and Shaanxi where we are selected as their respective Ministry of Education’s official provincial education platforms.”

“We are also excited about our achievements in our gaming business in 2020, as we continued to grow our revenue by investing our efforts in development of new titles, expanding the contents in existing titles, as well as strengthening our go-to-market capabilities. During the year, we ramped up content updates for our Eudemons IP and launched 7 expansion packs, leading to significant increase in user activities and engagement. Our flagship game Eudemons Online saw its MAU and DAU increased 49% and 46%, respectively year-over year, providing a solid foundation for sustained, long-term growth of the game and the overall Eudemons IP. We are also pleased with the progress we have made in developing a brand new next generation 3D Eudemons game, which will take our gamers’ experience to a whole new level. Last but not least, as the economy continued to recover from the pandemic, we saw an 8.4% increase in our gaming revenue in the second half compared to the first half, and we expect this momentum to continue into 2021 as we maintain our strategy to maximize IP value with a series of new games to be launched in the new year.”


[1] Based on report issued by Futuresource Consulting dated 15th February 2021, incorporating actual shipment volumes (excluding China) of the Company


Fiscal Year 2020 Financial Highlights

  • Revenue was RMB6,137.6 million, representing a 5.9% increase year-over-year.
  • Revenue from the gaming business was RMB3,432.7 million, representing 55.9% of the Company’s total revenue and registering a 4.0% increase year-over-year.
  • Revenue from the education business was RMB2,443.9 million, representing 39.8% of the Company’s total revenue and registering a 2.0% increase year-over-year.
  • Gross profit was RMB4,171.3 million, representing an 8.2% increase year-over-year.
  • Core segmental profit[2] from the gaming business was RMB1,963.5 million, representing a 2.1% increase year-over-year.
  • Core segmental loss[2] from the education business was RMB585.5 million, representing an 11.6% increase year-over-year.
  • Cash inflow from operating activities was RMB1,329.7 million, representing a 13.1% increase year-over-year.
  • EBITDA was RMB1,621.5 million, representing a 30.2% increase year-over-year.
  • Non-GAAP operating profit[3] was RMB1,314.8 million, representing a 24.0% increase year-over-year.
  • Profit attributable to owners of the Company was RMB953.5 million, representing an 18.1% increase year-over-year.
  • Non-GAAP profit attributable to owners of the Company[3] was RMB1,142.3 million, representing a 19.6% increase year-over-year.
  • The Company declared a final dividend of HK$0.25 per ordinary share (2019: HK$0.25 per ordinary share), subject to approval at the coming annual general meeting. Total dividends for the year amounted to HK$0.50 per ordinary share (2019: HK$0.40 per ordinary share), representing approximately 25.9% of the total profit attributable to the owners for the year. During 2020, the Group repurchased over 7.5 million ordinary shares, which accounts for 1.3% of issued shares as of 31 December 2020, for a total consideration of approximately HK$128.0 million. The total dividends plus share buy-backs for the year accounted for 37.3% of the profit attributable to the owners for the year.


[2] Core segmental profit (loss) figures are derived from the Company’s reported segmental profit (loss) figures (presented in accordance with Hong Kong Financial Reporting Standard (“HKFRS”) 8) but exclude non-core/operating, non-recurring or unallocated items including government grants, fair value change and finance costs of financial instruments, intercompany finance costs, impairment loss (net of reversal), impairment of goodwill and intangible assets, fair value change and exchange loss on convertible preferred shares, fair value change on financial assets at fair value through profit or loss (“FVTPL”), fair value change and exchange gain on derivative financial instruments and interest and exchange gain on convertible and exchangeable bonds.


[3] To supplement the consolidated results of the Group prepared in accordance with HKFRSs, the use of non-GAAP operating profit and non-GAAP profit attributable to owners of the Company measures are provided solely to enhance the overall understanding of the Group’s current financial performance. The non-GAAP measures are not expressly permitted measures under HKFRSs and may not be comparable to similarly titled measures for other companies. The non-GAAP measures of the Group exclude share-based payments expense, amortisation of intangible assets arising on acquisition of subsidiaries, impairment of goodwill and intangible assets, fair value gain on financial assets at FVTPL, fair value gain on derivative financial instruments, finance costs, interest income on pledged bank deposits and exchange gain (loss) on financial assets at FVTPL, bank borrowings, convertible and exchangeable bonds and derivative financial instruments.


Segmental Financial Highlights


FY2020

FY2019

Variance


(RMB ‘000)


Gaming


Education

Gaming

Education

Gaming

Education

Revenue


3,432,666


2,443,941

3,299,626

2,395,398

4.0%

2.0%

Gross Profit


3,301,513


758,605

3,165,500

713,009

4.3%

6.4%

Gross Margin


96.2%


31.0%

95.9%

29.8%

+0.3 ppts

+1.2 ppts

Core Segmental
Profit (Loss)[2]


1,963,534


(585,481)

1,923,262

(524,458)

2.1%

11.6%

Segmental Operating
Expenses

–       Research and
        development


(634,272)


(536,678)

(557,561)

(491,261)

13.8%

9.2%

–       Selling and
        marketing


(401,142)


(483,215)

(385,921)

(508,088)

3.9%

-4.9%

–       Administrative


(306,586)


(291,157)

(306,434)

(254,866)

0.0%

14.2%


Gaming Business

Our gaming business revenue increased by 4.0% year-over-year to RMB3,432.7 million in 2020. While Covid-19 resulted in a slowdown in spending growth of our high-paying user segment in the first half due to the pandemic, our gaming revenue regained growth momentum in the second half with an 8.4% increase half-over-half as the economy continued to recover. Despite the challenges brought by the pandemic, our overseas markets also demonstrated a strong performance with significant year-over-year increase in revenue, representing 13.7% of total gaming revenue in 2020.

Eudemons, our flagship IP, recorded solid revenue growth in 2020, driven primarily by significant increase in active users. We forged ahead in our efforts to grow a larger active user base, drive higher user engagement and build stronger IP recognition, which all served to drive our future growth. During the year, we took a more aggressive approach to enhance gamers’ loyalty by launching 7 new expansion packs and a new Eudemons IP game. As a result, the MAU and DAU of Eudemons IP surged 22% and 37% in 2020 respectively.

The focus of Heroes Evolved during the year continued to be on expanding and optimizing its user base. Through effective marketing and promotion campaigns including collaboration with two well-known anime, OVERLORD and That Time I Got Reincarnated as a Slime, Heroes Evolved expanded its gamer base to ACGN[4]  field, forming a strong high paying user base foundation for future monetization. During the year, Heroes Evolved Pocket Version was also recommended by App Store and hit the iOS Top 10 free gaming app chart for the first time. Meanwhile, our other major IP Conquer Online recorded revenue growth of 6.3% in 2020, as a result of robust content and user experience enhancement with multiple expansion packs launched during the year.

Looking forward, we expect to drive revenue and profit growth on multiple fronts, including maximizing our IP values through launching new games and entering into new genres, as well as expanding our IP portfolio and IP collaboration. Our pipeline is robust with multiple new games ready to be launched in 2021. We expect to launch two Eudemons IP games, namely Eudemons Mobile II and Legends of Eudemons, as well as Neopets Match 3 and Neopets Island Builders under the Neopets IP during this year. In terms of new IP, our first ACGN-style mobile game Under Oath is also scheduled to be launched in collaboration with Bilibili in the third quarter of 2021.


[4] ACGN refers to Animation, Comic, Game and Novel


Education Business

In 2020, our education business recorded revenue of RMB2,443.9 million, up 2.0% year-over-year. The outbreak of Covid-19 has brought challenges but also opportunities, as blended learning model has become a necessity and we saw its adoption continuing to accelerate during the year. We have successfully capitalized on this opportunity with our unique blended learning solution, and have been engaging in active discussions with multiple countries in the pipeline.

In August 2020, we signed a 5-year MOU with Ministry of Education of Egypt (Egypt MOE) and commenced the implementation to deliver a country-wide blended learning solution that integrates our Promethean, Edmodo and several other flagship product offerings. In addition, we were in close discussion during the year with education authorities in Thailand, Ghana, Malaysia and several other countries. We expect our country rollout to be executed with a multi-pronged revenue model, including sale of hardware, realizing software revenue in the form of SaaS, subscription or licensing, as well as long-tail revenue in the form of contents and services. 

Our classroom technology subsidiary Promethean continued to maintain its market leadership position during the year with its unique product value proposition, a well-established and growing channel of distributors and partners, as well as a high level of brand equity globally. Shipment of Promethean Interactive Flat Panel recorded 16.4% year-over-year increase in 2020, as we successfully transitioned into a virtual sales and marketing model in view of the pandemic. We also saw significant revenue momentum in the second half as Promethean’s revenue grew by 8.0% half-over-half compared to the first half. Furthermore, we continued to enhance Promethean’s operating efficiency as we achieved reduction in all of our major core direct cost items including freight, warranty and warehousing costs, leading to gross margin increase from 30.1% in 2019 to 33.6% in 2020.

In China, we continued to execute our strategy to broaden user coverage and drive user engagement in order to build a strong foundation to scale monetization. With monthly teachers’ active installed base of over 1.5 million in December 2020, 101 Education PPT has become one of the most popular lesson preparation and delivery platforms in China, and we have started to pilot monetization approaches such as live broadcast service. Our other flagship product, the One-Stop Learning platform, recorded tenfold surge in average MAU to 2 million compared to 2019, and expanded its penetration to nine provinces during the year, including the provinces of Hubei, Henan and Shaanxi where we are selected as their respective education ministries official provincial education platforms.  We believe the broad coverage of provinces will enable us to move toward the scaling of monetization, as education authorities are increasingly embracing the use of technologies in learning and teaching as part of the macro trend. Another major milestone achieved during the year is our  successful pilot carried out for our Virtual Lab platform across 6 provinces in partnership with the National Center for Educational Technology (“NCET”), a unit directly affiliated to Chinese Ministry of Education (MOE). The virtual experimental teaching platform was well received by the participating teachers and students, and we expect to roll out the solution across the country to start generating SaaS revenue in 2021.  

With our unique blended learning solutions, we are well positioned to elevate teaching and learning experience and capture market opportunities globally in a world of ever-increasing demand for education technology. We are optimistic about our growth trajectory in 2021 as we continue to capitalize on our market leadership position, our broad market coverage and our ability to execute country-level rollouts.

– End –

Management Conference Call

NetDragon’s management team will hold a conference call and webcast at 10:00amHong Kong time on 26 March 2021 to discuss the results and recent business developments.

Details of the live conference call are as follows:

International                                  

+852 2112 1888

Mainland China                              

4008 428 338

HK (China)                                    

+852 2112 1888

US                                                 

1 866 226 1406

UK                                                 

0800 032 2849

Passcode                                      

7636526#

A live and archived webcast of the conference call will be available on the Investor Relations section of NetDragon’s website at http://ir.nd.com.cn/en/category/webcast. Participants in the live webcast should visit the aforementioned website 10 minutes prior to the call, then click on the icon for “2020 Annual Results Conference Call” and follow the registration instructions.

About NetDragon Websoft Holdings Limited

NetDragon Websoft Holdings Limited (HKSE: 0777) is a global leader in building internet communities with a long track record of developing and scaling multiple internet and mobile platforms that impact hundreds of millions of users, including previous establishments of China’s first online gaming portal, 17173.com, and China’s most influential smartphone app store platform, 91 Wireless.

Established in 1999, NetDragon is one of the most reputable and well-known online game developers in China with a history of successful game titles including Eudemons Online, Heroes Evolved and Conquer Online. In recent years, NetDragon has also started to scale its online education business on the back of management’s vision to create the largest global online learning community, and to bring the “classroom of the future” to every school around the world.

For investor enquiries, please contact:

NetDragon Websoft Holdings Limited
Ms. Maggie Zhou
Senior Director of Investor Relations
Tel.: +852 2850 7266 / +86 591 8390 2825
Email: [email protected]
Website: ir.nd.com.cn

 


CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME


FOR THE YEAR ENDED
31
DECEMBER
 2020


2020

2019


RMB’000

RMB’000


Revenue


6,137,640

5,793,075

Cost of revenue


(1,966,376)

(1,937,823)


Gross profit


4,171,264

3,855,252

Other income and gains


230,884

139,568

Impairment loss under expected credit loss model, 
    

net of reversal


1,607

(26,491)

Selling and marketing expenses


(893,513)

(915,754)

Administrative expenses


(903,111)

(883,083)

Development costs


(1,175,928)

(1,075,400)

Other expenses and losses


(326,817)

(307,820)

Share of losses of associates


(15,080)

(4,936)

Share of losses of a joint ventures


(1,783)

(3,370)


Operating profit


1,087,523

777,966

Interest income on pledged bank deposits


3,263

3,181

Exchange gain (loss) on financial assets at
   

fair value through profit or loss, bank borrowings,
   

convertible preferred shares, convertible and
   

exchangeable bonds and derivative financial instruments


45,302

(1,052)

Fair value change on convertible preferred shares



110,697

Fair value change on financial assets at fair value
   

through profit or loss

 


51,733

 

219

Fair value change on derivative financial instruments


43,323

Finance costs


(157,680)

(24,742)


Profit before taxation


1,073,464

866,269

Taxation


(217,644)

(163,214)


Profit for the year


855,820

703,055

Other comprehensive (expense) income for the year,
   

net of income tax:

Item that may be reclassified subsequently to profit or loss:

Exchange differences arising on translation of
   

foreign operations


(11,568)

5,517

Item that will not be reclassified to profit or loss:

Fair value gain on equity instruments at fair
   

value through other comprehensive income


6,042

878

Other comprehensive (expense) income for the year


(5,526)

6,395

 

Total comprehensive income for the year

 

 


850,294

 

 

709,450

 

Profit (loss) for the year attributable to:

– Owners of the Company


953,501

807,212

– Non-controlling interests


(97,681)

(104,157)


855,820

703,055

Total comprehensive income (expense) for the year 
   

attributable to:

– Owners of the Company


944,235

813,456

– Non-controlling interests


(93,941)

(104,006)


850,294

709,450


RMB cents

RMB cents


Earnings per share

– Basic


171.19

152.68

– Diluted


170.96

152.17

 

 


CONSOLIDATED STATEMENT OF FINANCIAL POSITION


AT 31 December 2020


2020

2019


RMB’000

RMB’000


Non-current assets

Property, plant and equipment


1,992,708

1,918,697

Right-of-use assets


455,011

467,250

Investment properties


76,529

95,090

Intangible assets


625,771

675,737

Interests in associates


49,659

54,655

Interests in joint ventures


16,563

12,346

Equity instruments at fair value through
   

other comprehensive income

 

 


10,808

 

4,514

Financial assets at fair value through profit or loss


281,194

Loan receivables


10,421

9,573

Other receivables, prepayments and deposits


62,841

57,829

Deposits made for acquisition of property,
   

plant and equipment

 


3,630

 

11,486

Goodwill


241,332

313,328

Deferred tax assets


43,437

47,317


3,869,904

3,667,822


Current assets

Properties under development


263,915

469,070

Properties for sale


253,367

20,640

Inventories


316,909

237,478

Loan receivables


22,042

27,354

Trade receivables


525,353

689,360

Other receivables, prepayments and deposits


399,537

328,369

Contract assets


12,236

18,333

Amount due from a related company


47

849

Amounts due from associates



2,262

Amounts due from joint ventures


974

279

Amount due from a director



400

Tax recoverable


14,035

6,689

Financial assets at fair value through profit or loss


5,781

1,492

Restricted bank balances


15,611

15,089

Pledged bank deposits


146,073

145,787

Bank deposit with original maturity over three months


33,021

Bank balances and cash


4,114,410

2,125,637


6,123,311

4,089,088


Current liabilities

Trade and other payables


1,091,369

980,522

Contract liabilities


405,483

529,497

Lease liabilities


56,224

54,603

Provisions


71,501

69,867

Derivative financial instruments


40,894

Amount due to a related company



105

Amounts due to associates


3,484

257

Amount due to a joint venture


593

Convertible and exchangeable bonds


15,351

Bank borrowings


154,597

161,135

Dividend payable to non-controlling interests


99

Tax payable


121,083

107,120


1,960,678

1,903,106


Net current assets


4,162,633

2,185,982


Total assets less current liabilities


8,032,537

5,853,804


Non-current liabilities

Other payables


5,409

16,275

Convertible preferred shares



Convertible and exchangeable bonds


976,765

Bank borrowings


191,073

246,068

Lease liabilities


116,453

108,803

Deferred tax liabilities


90,907

121,610


1,380,607

492,756


Net assets


6,651,930

5,361,048


Capital and reserves

Share capital


40,951

38,822

Share premium and reserves


6,766,393

5,557,499

Equity attributable to owners of the Company


6,807,344

5,596,321

Non-controlling interests


(155,414)

(235,273)


6,651,930

5,361,048

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/netdragon-announces-fiscal-year-2020-financial-results-301256887.html

SOURCE NetDragon Websoft Holdings Limited

Empire Life Investments appoints Ian Fung, Portfolio Manager, Fixed Income

Canada NewsWire

TORONTO, March 26, 2021 /CNW/ – Empire Life Investments Inc. today announced the appointment of Ian Fung, CFA, as Portfolio Manager, Fixed Income.

Ian will be the lead portfolio manager on the Empire Life Bond GIF*, as well as the fixed income portion of the Empire Life Emblem Portfolios. Geoff Johnston, CFA, Senior Portfolio Manager, Fixed Income will continue to consult on the management of the funds, but will transition to taking on a greater role in the management of fixed income investments for our general fund which supports our annuity and insurance products.

Ian has more than 10 years of investment industry experience, holding progressive roles at a number of Canadian independent wealth management firms. Most recently, in addition to his role as Portfolio Manager, where he focused on managing North American credit portfolios, he was also responsible for trading securities and being an active member of his former firm’s Investment Committee.

“We’re very excited to have Ian join our fixed income team. He brings with him a wealth of knowledge in this space and a management style that aligns well with our disciplined investment approach,” says Patrick McGrath, Vice-President, Fixed Income and Private Placements.

About Empire Life Investments Inc.

Empire Life Investments Inc. is a wholly-owned subsidiary of The Empire Life Insurance Company. The company manages and offers mutual funds and is the portfolio manager of the Empire Life segregated funds, including the Empire Life Guaranteed Investment Funds. As of December 31, 2020, Empire Life had total assets under management of $18.8 billion. Follow us on social media @EmpireLife or visit www.empire.ca for more information.

*This is the marketing name for the fund. The legal name excludes “Empire Life” and “GIF” and includes “Fund” at the end of the name.

SOURCE The Empire Life Insurance Company